Defactinib
Drug
Verastem, Inc.
Total Payments
$356,206
Transactions
77
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $5,424 | 8 | 1 |
| 2019 | $350,783 | 69 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $355,442 | 76 | 99.8% |
| Consulting Fee | $764.75 | 1 | 0.2% |
Payments by Type
Research
$355,442
76 transactions
General
$764.75
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer | Verastem, Inc. | $222,815 | 0 |
| Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma ParticipantsVS-6063-203 | Verastem, Inc. | $111,073 | 0 |
| Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer | Verastem, Inc. | $10,403 | 0 |
| Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma | Verastem, Inc. | $2,165 | 0 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | Verastem, Inc. | $2,060 | 0 |
| IND 136884/ VS-6063-101 | Verastem, Inc. | $1,236 | 0 |
| IND142882 | Verastem, Inc. | $1,236 | 0 |
| 201510157 | Verastem, Inc. | $1,030 | 0 |
| IST-6063-001 | Verastem, Inc. | $1,030 | 0 |
| ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK | Verastem, Inc. | $1,030 | 0 |
| IST-6063-009 | Verastem, Inc. | $618.00 | 0 |
| IST-6063-007 | Verastem, Inc. | $515.00 | 0 |
| 6063-203 | Verastem, Inc. | $230.00 | 0 |
Top Doctors Receiving Payments for Defactinib
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Ft Myers, FL | $355,442 | 76 |
| , MD | Medical Oncology | New Haven, CT | $764.75 | 1 |
Ad
Manufacturing Companies
- Verastem, Inc. $356,206
Product Information
- Type Drug
- Total Payments $356,206
- Total Doctors 1
- Transactions 77
About Defactinib
Defactinib is a drug associated with $356,206 in payments to 1 healthcare providers, recorded across 77 transactions in the CMS Open Payments database. The primary manufacturer is Verastem, Inc..
Payment data is available from 2019 to 2020. In 2020, $5,424 was paid across 8 transactions to 1 doctors.
The most common payment nature for Defactinib is "Unspecified" ($355,442, 99.8% of total).
Defactinib is associated with 13 research studies, including "Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer" ($222,815).